top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

10.74 -0.87 (-7.49%)
Streaming Delayed Price Updated: 11:35 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy Pipeline 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
Late-breaking poster presentation to highlight new immunogenicity data from ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Secures $10 Million in Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page